Please provide your email address to receive an email when new articles are posted on . The addition of camrelizumab to platinum-containing intensive chemotherapy improved response for certain ...
BioNTech and Bristol Myers Squibb share positive data from Phase 2 trial of pumitamig plus chemotherapy for triple-negative ...
The 5 most-read breast cancer articles on AJMC.com this year included FDA approvals, emerging therapies for metastatic breast ...
Sacituzumab govitecan targets Trop-2 and delivers potent chemo directly to TNBC cells. PARP inhibitors are effective in TNBC patients with BRCA mutations. Immune checkpoint inhibitors benefit patients ...
An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of. For patients with triple-negative breast cancer, there are now several clinical ...
Scientists have uncovered a powerful new antibody that disrupts a key protein helping triple-negative breast cancer survive and evade immunity. Triple-negative breast cancer (TNBC) is considered one ...
The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending pembrolizumab (Keytruda, Merck Sharp and Dohme) in combination with chemotherapy for women ...
Findings set the stage for further investigation of hSFRP2 mAb as a targeted therapy for triple-negative breast cancer.
Triple negative breast cancer (TNBC) represents approximately 10-15% of all breast cancer diagnoses but accounts for a disproportionately high percentage of breast cancer deaths. What sets this ...
– With Two Positive Phase 3 Trials, Trodelvy Has Potential as the First and Only ADC to be a Backbone Standard of Care for All First-Line Metastatic TNBC Patients Regardless of PD-L1 Status – Gilead ...
Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback